Loading clinical trials...

Immunogenicity of COVID-19 Vaccination in Immunocompromised Patients (Auto-COVID-VACC) | Clinical Trials | Clareo Health

ACTIVE_NOT_RECRUITING

Immunogenicity of COVID-19 Vaccination in Immunocompromised Patients (Auto-COVID-VACC)

NCT05597761•Oliver Cornely, MD

View on ClinicalTrials.gov

Summary

This multicenter, prospective, non-interventional study aims to evaluate data on humoral and cellular immune response generated within the COVID-19 vaccination standard in immunocompromised patients.

Detailed Description

This study aims to analyze the immune response data generated within the procedures of the standard-of-care COVID-19 vaccination. for immunocompromised patients. Additional blood will be drawn from the patients at each visit defined within the vaccination standard by using the same vein puncture as used for blood drawings of routine blood samples. Study related blood samples will be used for evaluation of T and B cell response to COVID-19 vaccinations. For this study, no additional visits or invasive procedures will be performed in addition to the standard interventions.

Eligibility

Age

18 - No limit years

Sex

ALL

Healthy Volunteers

Inclusion Criteria

•Patient is vaccinated according to the recent version of the COVID-19 vaccination standard for immunocompromised patients.
•Patient is 18 years of age or older at enrollment.
•Written informed consent from patient has been obtained prior to any study related procedures

Exclusion Criteria

•Patient is not vaccinated according to the recent version of the COVID-19 vaccination standard. Patient has a positive SARS-CoV-2 antigen test at the first visit.

Locations (3)

Klinik für Hämatologie, Onkologie, Hämostaseologie und Stammzelltransplantation (Med. Klinik IV) Uniklinik der RWTH Aachen

Aachen, North Rhine-Westphalia, Germany

University Hospital of Cologne

Cologne, North Rhine-Westphalia, Germany

Universitätsklinikum Essen Klinik für Hämatologie und Stammzellentransplantation

Essen, North Rhine-Westphalia, Germany

Key Dates

Start Date

May 15, 2023

Primary Completion Date

September 30, 2025

Completion Date

December 31, 2025

Last Updated

May 14, 2025

Enrollment

ACTUAL participants

Conditions

COVID-19AdultImmunocompromised Patients

Testing the Addition of an Anti-Cancer Drug, Triapine, to the Usual Radiation Therapy for Recurrent Glioblastoma or Astrocytoma

NCT06860594

Astrocytoma, IDH-Mutant, Grade 2Recurrent Adult Diffuse Hemispheric Glioma, H3 G34-Mutant+5 more

View study

RECRUITINGPHASE1

Azacitidine and Abatacept in Relapsed or Refractory T-Cell Lymphoma

NCT07388563

Lymphoma, T Cell, PeripheralT-cell Lymphoma+4 more

View study

Data Source & Attribution

This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.

ClinicalTrials.gov last update: May 14, 2025Data synced to Clareo: March 29, 2026

Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.

Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.

View ClinicalTrials.gov Terms and Conditions

Immunogenicity of COVID-19 Vaccination in Immunocompromised Patients (Auto-COVID-VACC)

Inclusion Criteria

Exclusion Criteria

Testing the Addition of an Anti-Cancer Drug, Triapine, to the Usual Radiation Therapy for Recurrent Glioblastoma or Astrocytoma

Azacitidine and Abatacept in Relapsed or Refractory T-Cell Lymphoma

OSA Risk Level in Dental Patients and Correlation With Complications After General Anesthesia

A Study of a Deuterated Psilocin Analog (CYB003) in Humans With Major Depressive Disorder

The Impact of Paramedic Training in Simulation on the Experience of Patients Treated for Malignant Brain Tumors in Neurosurgery (IPSIMANON)

Turkish Validity and Reliability Study of PRevention of Toxic Chemicals in the Environment for Children Tool